R-ondansetron

Drug Profile

R-ondansetron

Latest Information Update: 22 Feb 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sepracor
  • Class Antiemetics
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Nausea and vomiting

Most Recent Events

  • 22 Feb 2006 No development reported - Preclinical for Emesis in USA (unspecified route)
  • 18 Apr 2001 Preclinical development for Emesis in USA (Unknown route)
  • 08 Mar 2000 No-Development-Reported for Emesis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top